CRP and hydrops fetalis: CANTOS study demonstrated that therapy with canakinumab, an IL-1β inhibitor, resulted in a significant decrease in CRP and reduced rate of HFH and the composite of HFH or HF-related mortality during a median follow-up of 3.7 years in post-infarct patients with CRP ≥ 2 mg/L regardless of LVEF [26,57].